AU2004259009A1 - Azepine derivatives as pharmaceutical agents - Google Patents

Azepine derivatives as pharmaceutical agents Download PDF

Info

Publication number
AU2004259009A1
AU2004259009A1 AU2004259009A AU2004259009A AU2004259009A1 AU 2004259009 A1 AU2004259009 A1 AU 2004259009A1 AU 2004259009 A AU2004259009 A AU 2004259009A AU 2004259009 A AU2004259009 A AU 2004259009A AU 2004259009 A1 AU2004259009 A1 AU 2004259009A1
Authority
AU
Australia
Prior art keywords
optionally substituted
heterocyclyl
ring
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004259009A
Other languages
English (en)
Inventor
Brenton T. Flatt
Xiao-Hui Gu
Richard Martin
Tie-Lin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2004259009A1 publication Critical patent/AU2004259009A1/en
Assigned to EXELIXIS, INC. reassignment EXELIXIS, INC. Request for Assignment Assignors: X-CEPTOR THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004259009A 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents Abandoned AU2004259009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
US60/489,854 2003-07-23
PCT/US2004/023745 WO2005009387A2 (en) 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
AU2004259009A1 true AU2004259009A1 (en) 2005-02-03

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004259009A Abandoned AU2004259009A1 (en) 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents

Country Status (14)

Country Link
US (1) US8466143B2 (enExample)
EP (1) EP1648408A4 (enExample)
JP (1) JP4679517B2 (enExample)
KR (1) KR20060052867A (enExample)
CN (1) CN1852748A (enExample)
AU (1) AU2004259009A1 (enExample)
BR (1) BRPI0412262A (enExample)
CA (1) CA2532798C (enExample)
CR (1) CR8258A (enExample)
EC (1) ECSP066392A (enExample)
IL (1) IL173287A0 (enExample)
NO (1) NO20060871L (enExample)
RU (1) RU2006105646A (enExample)
WO (1) WO2005009387A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US7402680B2 (en) 2003-09-17 2008-07-22 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
ATE420091T1 (de) 2005-03-14 2009-01-15 Glaxo Group Ltd Kondensierte thiazolderivate mit affinität für den histamin-h3-rezeptor
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
JP5551708B2 (ja) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
US8907097B2 (en) 2008-10-31 2014-12-09 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
CN102712643B (zh) 2009-05-22 2015-12-16 Abbvie公司 5-ht受体的调节剂及其使用方法
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
KR101770979B1 (ko) * 2010-05-21 2017-08-24 애브비 인코포레이티드 5­ｈｔ 수용체의 조절제 및 이의 사용방법
WO2012154261A1 (en) 2011-02-18 2012-11-15 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
JP7224102B2 (ja) * 2014-11-21 2023-02-17 アカーナ・セラピューティクス・リミテッド 疾患治療用の縮合二環式化合物
RU2021100040A (ru) 2014-12-22 2021-02-02 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3715348A1 (en) 2015-03-26 2020-09-30 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
JP2019517478A (ja) * 2016-05-25 2019-06-24 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． ファルネソイドｘレセプター（ｆｘｒ）モジュレーターとの併用療法
SG11201810292YA (en) * 2016-05-25 2018-12-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
WO2018222876A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
CN112312909B (zh) 2018-01-26 2024-07-02 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
AU2019212800B2 (en) * 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
CA2297988A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
CN1852748A (zh) 2006-10-25
IL173287A0 (en) 2006-06-11
WO2005009387A3 (en) 2006-03-02
US8466143B2 (en) 2013-06-18
NO20060871L (no) 2006-04-24
JP2006528637A (ja) 2006-12-21
ECSP066392A (enExample) 2007-01-26
WO2005009387A2 (en) 2005-02-03
CA2532798A1 (en) 2005-02-03
BRPI0412262A (pt) 2006-09-19
EP1648408A1 (en) 2006-04-26
CA2532798C (en) 2013-02-19
RU2006105646A (ru) 2007-09-10
EP1648408A4 (en) 2006-11-29
JP4679517B2 (ja) 2011-04-27
US20070015746A1 (en) 2007-01-18
KR20060052867A (ko) 2006-05-19
CR8258A (es) 2006-08-30

Similar Documents

Publication Publication Date Title
CA2532798C (en) Azepine derivatives as pharmaceutical agents
US8133992B2 (en) Azepinoindole and pyridoindole derivatives as pharmaceutical agents
CA2555279C (en) Azepinoindole derivatives as pharmaceutical agents
CA2633243C (en) Azepinoindole derivatives as pharmaceutical agents
JP2005531585A5 (enExample)
MXPA06000875A (en) Azepine derivatives as pharmaceutical agents

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EXELIXIS, INC.

Free format text: FORMER APPLICANT(S): X-CEPTOR THERAPEUTICS, INC.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period